SCHEMBL5466909

SCHEMBL5466909

CCOc1ccc(F)cc1NC(=O)Nc1ccc(N2CCNCC2)nc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLK2 P49760 2/20 0.46
DYRK1A Q13627 2/20 0.46
CLK3 P49761 1/20 0.46
KMT2A Q03164 4/20 0.46
MEN1 O00255 3/20 0.46
PABPC1 P11940 1/20 0.46
MAPT P10636 2/20 0.45
TP53 P04637 1/20 0.45
POLB P06746 1/20 0.45
BLM P54132 1/20 0.45
HDAC2 Q92769 5/20 0.45
HDAC3 O15379 4/20 0.45
MAPK7 Q13164 1/20 0.45
HDAC1 Q13547 1/20 0.43
MRGPRX1 Q96LB2 3/20 0.43
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
CASP3 P42574 1/20 0.42
SENP8 Q96LD8 1/20 0.42
SENP7 Q9BQF6 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5451401 0.90 KMT2A (0.51) CLK2DYRK1ACLK3KMT2AMEN1
SCHEMBL5467414 0.90 CLK2 (0.51) CLK2DYRK1ACLK3KMT2AMEN1
SCHEMBL5465368 0.90 KMT2A (0.51) CLK2DYRK1ACLK3KMT2AMEN1
SCHEMBL5466937 0.88 KMT2A (0.60) KMT2AMEN1PABPC1MAPTTP53
SCHEMBL5465441 0.88 MAPT (0.49) KMT2AMEN1PABPC1MAPTTP53
SCHEMBL5455937 0.87 MAPT (0.52) KMT2AMEN1MAPTTP53POLB
SCHEMBL5462442 0.84 WNT3A (0.51) KMT2AMEN1PABPC1MAPTTP53
SCHEMBL5469223 0.82 KDM4E (0.46) KMT2AMEN1PABPC1MAPTTP53
SCHEMBL5466152 0.82 KDM4E (0.48) KMT2AMEN1PABPC1MAPTTP53
SCHEMBL5452137 0.80 MEN1 (0.55) CLK2DYRK1ACLK3KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070249620-A1 Urea Derivative SANKYO COMPANY, LIMITED (JP) 2007-10-25 US disclosed
EP-1764360-A1 UREA DERIVATIVE Sankyo Company, Limited (JP) 2007-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249620-A1 Urea Derivative UGP2, SLC14A1, DGAT1 CLK2 2880/4885DYRK1A 2418/4885CLK3 2623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.